DK1146896T3 - Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger - Google Patents

Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger

Info

Publication number
DK1146896T3
DK1146896T3 DK00904496T DK00904496T DK1146896T3 DK 1146896 T3 DK1146896 T3 DK 1146896T3 DK 00904496 T DK00904496 T DK 00904496T DK 00904496 T DK00904496 T DK 00904496T DK 1146896 T3 DK1146896 T3 DK 1146896T3
Authority
DK
Denmark
Prior art keywords
human insulin
modified
acylated
formulations
formulations containing
Prior art date
Application number
DK00904496T
Other languages
Danish (da)
English (en)
Inventor
Kingman Ng
Shun Li
Eric Alan Watts
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1146896T3 publication Critical patent/DK1146896T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK00904496T 1999-01-26 2000-01-26 Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger DK1146896T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11729199P 1999-01-26 1999-01-26
PCT/US2000/001627 WO2000043034A2 (en) 1999-01-26 2000-01-26 Monodisperse hexameric acylated insulin analog formulations

Publications (1)

Publication Number Publication Date
DK1146896T3 true DK1146896T3 (da) 2002-09-02

Family

ID=22372048

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00904496T DK1146896T3 (da) 1999-01-26 2000-01-26 Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger

Country Status (9)

Country Link
EP (1) EP1146896B1 (es)
JP (1) JP2002535287A (es)
AT (1) ATE220917T1 (es)
AU (1) AU2624400A (es)
DE (1) DE60000288T2 (es)
DK (1) DK1146896T3 (es)
ES (1) ES2180511T3 (es)
PT (1) PT1146896E (es)
WO (1) WO2000043034A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
JP2005526126A (ja) * 2002-05-07 2005-09-02 ノボ　ノルディスク　アクティーゼルスカブ インスリンアスパルト及びインスリンデテミアを含む可溶性製剤
AU2003236201A1 (en) * 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
PL377813A1 (pl) 2002-11-26 2006-02-20 Biocon Limited Modyfikowane związki natriuretyczne, ich koniugaty oraz zastosowania
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
CN105801686B (zh) * 2004-07-19 2020-04-07 比奥孔有限公司 胰岛素-低聚物共轭物、制剂及其用途
CN101389650B (zh) * 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
ES2542146T3 (es) 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
EP2152245B1 (en) 2007-04-30 2015-12-02 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
EP2167032B1 (en) 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
RU2571857C2 (ru) 2008-03-18 2015-12-20 Ново Нордиск А/С Стабилизированные по отношению к протеазам ацилированные аналоги инсулина
EP2352513B1 (en) 2008-10-30 2016-09-14 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
AU2013346624B2 (en) 2012-11-13 2018-08-09 Adocia Quick-acting insulin formulation including a substituted anionic compound
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
HUE036702T2 (hu) 2013-10-07 2018-07-30 Novo Nordisk As Inzulinanalóg új származéka
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
TWI700091B (zh) * 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物
WO2018222787A1 (en) 2017-06-01 2018-12-06 Eli Lilly And Company Rapid-acting insulin compositions
WO2019034726A1 (en) 2017-08-17 2019-02-21 Novo Nordisk A/S NOVEL ACYLATED INSULIN ANALOGUES AND USES THEREOF
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2021033066A1 (en) * 2019-08-16 2021-02-25 Lamark Biotech Pvt Limited A formulation of insulin based on crystal-seeding in hydrogels and method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT921812E (pt) * 1996-06-20 2002-04-29 Novo Nordisk As Preparacoes de insulina contendo um halogenuro
JP3343129B2 (ja) * 1997-02-07 2002-11-11 ノボ ノルディスク アクティーゼルスカブ タンパク質の結晶化
ATE290877T1 (de) * 1998-01-09 2005-04-15 Novo Nordisk As Stabilisierte insulin-zubereitungen

Also Published As

Publication number Publication date
DE60000288D1 (de) 2002-08-29
ES2180511T3 (es) 2003-02-16
ATE220917T1 (de) 2002-08-15
EP1146896A2 (en) 2001-10-24
DE60000288T2 (de) 2003-01-16
JP2002535287A (ja) 2002-10-22
AU2624400A (en) 2000-08-07
WO2000043034A3 (en) 2000-12-28
PT1146896E (pt) 2002-10-31
WO2000043034A2 (en) 2000-07-27
EP1146896B1 (en) 2002-07-24

Similar Documents

Publication Publication Date Title
DK1146896T3 (da) Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger
WO2002043750A3 (en) Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
HUP0100243A2 (hu) Inzulint és/vagy inzulin-analógokat és azok származékait tartalmazó oldhatatlan készítmények, eljárás azok előállítására és alkalmazásuk a vércukor szintjének szabályozására
EP1808438A3 (en) Purification and stabilization of peptide and proteins in pharmaceutical agents
EP1234586A3 (en) Hepatoselective pharmaceutical actives
WO2007130113A3 (en) Parathyroid hormone analogues and methods of use
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
MY121291A (en) Fracture healing using pthrp analogs
WO2003053346A3 (en) Systems and methods for treating patients with processed lipoaspirate cells
EA200000748A1 (ru) Способ введения мономерных аналогов инсулина
AU563642B2 (en) Oral antidiabetic composition
NO20005625L (no) Anvendelse av toremifen og dens metabolske analoger, og deres farmasoytisk akseptable salter, estere, N-oksider og blanding av disse, i fremstilling av et farmasoytisk preparat for behandling av prostataintraepitelisk neoplasi (PIN)
HK1037142A1 (en) Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
BR9811755A (pt) Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica
KR950700326A (ko) 파라토르몬 단편, 이것의 제조방법 및 이것을 함유하는 약제(parathyroid hormone fragments, their preparation and medicaments containing the same)
CA2522146A1 (en) Uptake of macromolecules
AR036591A1 (es) Uso de la hl en hiperestimulacion ovarica controlada
HK1157635A1 (en) Metal-binding compounds and uses thereof
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
PT97878A (pt) Processo para a preparacao de uma composicao farmaceutica para uso oftalmico contendo hexetidina ou seus derivados ou sais
MX9704388A (es) Incremento de la concentracion de creatina y glicogeno en musculos.
TH12479B (th) สูตรผสมของสารคล้ายอินซูลิน